New natural noncannabinoid ligands for cannabinoid type-2 (CB2) receptors.
Since the discovery that Delta 9-tetrahydrocannabinol and related cannabinoids from Cannabis sativa L. act on specific physiological receptors in the human body and the subsequent elucidation of the mammalian endogenous cannabinoid system, no other natural product class has been reported to mimic the effects of cannabinoids. We recently found that N-alkyl amides from purple coneflower (Echinacea spp.) constitute a new class of cannabinomimetics, which specifically engage and activate the cannabinoid type-2 (CB2) receptors. Cannabinoid type-1 (CB1) and CB2 receptors belong to the family of G protein-coupled receptors and are the primary targets of the endogenous cannabinoids N-arachidonoyl ethanolamine and 2-arachidonoyl glyerol. CB2 receptors are believed to play an important role in distinct pathophysiological processes, including metabolic dysregulation, inflammation, pain, and bone loss. CB2 receptors have, therefore, become of interest as new targets in drug discovery. This review focuses on N-alkyl amide secondary metabolites from plants and underscores that this group of compounds may provide novel lead structures for the development of CB2-directed drugs.
Gertsch
Jürg
J
Institute of Pharmaceutical Sciences, ETH Zurich, Zürich, Switzerland. juerg.gertsch@pharma.ethz.ch
Raduner
Stefan
S
Altmann
Karl-Heinz
KH
D002186:Cannabinoids / Q000737:chemistry* / Q000494:pharmacology; D015195:Drug Design; D006801:Humans; D007155:Immunologic Factors / Q000737:chemistry / Q000494:pharmacology; D008024:Ligands; D018716:Molecular Mimicry; D010944:Plants / Q000737:chemistry; D043885:Receptor, Cannabinoid, CB2 / Q000819:agonists / Q000737:chemistry*; D015398:Signal Transduction
D002186:Cannabinoids; D007155:Immunologic Factors; D008024:Ligands; D043885:Receptor, Cannabinoid, CB2